ENTA
- Enanta Pharmaceuticals, Inc.
()
Overview
Company Summary
Enanta Pharmaceuticals, Inc., also known as ENTA, is a biotechnology company specializing in the research and development of small molecule drugs for infectious diseases. The company aims to discover and develop innovative therapies that address significant unmet medical needs, particularly in the areas of viral hepatitis, respiratory tract infections, and other viral infections.
Enanta focuses on developing direct-acting antiviral (DAA) medications that target specific viral proteins to inhibit replication and viral spread. These medications have shown efficacy in treating chronic hepatitis C virus (HCV) infections, a significant public health concern affecting millions of people worldwide.
The company's most notable achievement to date is its collaboration with pharmaceutical giant AbbVie to develop glecaprevir/pibrentasvir (G/P), a pan-genotypic DAA therapy for the treatment of HCV. G/P has been approved in multiple countries and has demonstrated high cure rates across all six major HCV genotypes. This partnership has granted Enanta substantial financial support and royalties from sales of the drug.
Additionally, Enanta Pharmaceuticals has ongoing research programs focused on the discovery and development of novel antibiotics for the treatment of multidrug-resistant bacteria, including drug-resistant Gram-negative pathogens.
Overall, Enanta Pharmaceuticals specializes in the development of innovative antiviral and antibiotic drugs aimed at addressing unmet medical needs in the infectious diseases field.